Overview

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Denosumab